MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Hypoglycemia (binds insulin receptor at higher doses) Theoretical organ enlargement with chronic high-dose Theoretical concerns in active malignancy (IGF-1 axis) Known interactions Insulin / sulfonylureas (hypoglycemia risk) Concurrent rhGH not standard Contraindications Active malignancy (IGF-1 axis growth signaling) Pregnancy/lactation (unstudied) Diabetic retinopathy (theoretical exacerbation) REGULATORY STATUS FDA Not FDA-approved
STAT (February 2026) describes the gap between community claims and human data as "staggering." TB-500 preclinical data: muscle, heart, cornea, skin The TB-500 data is less voluminous than that of BPC-157 but more diversified in research teams
Compounds such as BPC-157, KPV, and GHK-Cu can be studied for their potential roles in supporting gastrointestinal integrity, cellular regeneration, and tissue recovery
Kisspeptin research in this population is among the most compelling available
Without training or a deficit, there's no fat being burned for it to transport
